Last reviewed · How we verify
Pulmonary Arterial Hypertension (PAH)
Approved treatments
- Remodulin · United Therap
Remodulin works by activating the prostacyclin receptor, which causes blood vessels to relax and widen. - Tracleer · AstraZeneca
- Opsumit · AstraZeneca
Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure. - prostacyclin · United Therapeutics
- Ilomedin · Prim PD Dr Afshin Assadian
- Adempas · University of Colorado, Denver
- Procylin
Procylin works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow. - Revatio · Pfizer Inc.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels and enabling penile smooth muscle relaxation. - Flolan · AstraZeneca
Flolan works by binding to the prostacyclin receptor, causing blood vessels to relax and dilate. - Letairis · Gilead Sciences
- Uptravi · AstraZeneca
Uptravi works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow. - Adempas · Bayer
Adempas works by stimulating the soluble guanylate cyclase enzyme to increase levels of cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax blood vessels. - Sitaxsentan · Pfizer
- Ventavis · Meshalkin Research Institute of Pathology of Circulation
- Viagra · Pfizer Inc.
Selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels to relax smooth muscle in the corpus cavernosum and pulmonary vasculature.
Clinical guidelines
- FDA label — 1L
Sildenafil is indicated for the treatment of pulmonary arterial hypertension. - FDA label — 1L
Sildenafil is indicated for the treatment of pulmonary arterial hypertension.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: